The NHS is poised to introduce a pioneering gene-editing therapy for beta thalassaemia, a genetic blood disorder that impairs haemoglobin production, the protein in red blood cells that transports oxygen throughout the body. This new treatment, utilising Crispr technology, offers a potentially permanent solution, potentially eliminating the lifelong need for regular blood transfusions, which patients typically undergo every three to five weeks.

Beta thalassaemia primarily affects individuals of Mediterranean, South Asian, Southeast Asian, and Middle Eastern descent, causing severe symptoms such as fatigue, weakness, and shortness of breath, and significantly shortening life expectancy. The therapy involves extracting stem cells from the patient’s bone marrow, reprogramming them to produce healthy haemoglobin, and reintroducing them into the body. Before the new cells are implanted, patients must undergo chemotherapy to eliminate the existing, malfunctioning cells.

Unlike traditional approaches that might attempt to directly repair the genetic defect, this therapy cleverly reactivates the body’s ability to produce foetal haemoglobin by disabling a genetic switch known as BCL11A. This switch typically shuts off foetal haemoglobin production after birth, but by keeping it active, the therapy ensures that patients can produce a functional form of haemoglobin unaffected by the disorder.

Clinical trial data have shown promising results, with most patients who received the treatment not needing blood transfusions for at least a year. Developed by Vertex and priced at £1.6 million per patient, the therapy has been approved by the National Institute of Health and Care Excellence (NICE). The NHS has negotiated a reduced price, making the treatment accessible to eligible patients across the UK.